Rising Specialty Pharmacy Demand Will Unlock Future Healthcare Potential

Published
18 Jul 24
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
US$367.57
21.0% undervalued intrinsic discount
14 Aug
US$290.35
Loading
1Y
-13.8%
7D
7.1%

Author's Valuation

US$367.6

21.0% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on07 May 25
Fair value Decreased 10%

Shared on30 Apr 25
Fair value Increased 7.52%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on16 Apr 25
Fair value Increased 0.14%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 5.93%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Increased 0.17%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Decreased 0.98%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on10 Mar 25
Fair value Decreased 3.76%

AnalystConsensusTarget has decreased revenue growth from 6.4% to 3.6%.